1-5 of 5
Dimitrios Drekolias
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax:  a multinational retrospective cohort study

Free
Curtis Lachowiez, Andy Kaempf, Jad Othman, Seongseok Yun, Mael Heiblig, Michael Heuser, Rabia Shahswar, Anand Patel, Rafael Madero-Marroquin, Joseph Cannova, Irene Zacheo, Federica Monaco, Dimitrios Drekolias, Fatima Tuz Zahra, Amine Belhabri, Urbain Tauveron-Jalenques, Emmanuelle Tavernier, Martin Carre, Gaspar Aspas Requena, Nicola Long, Rachel Cook, Elie Traer, Ronan Swords, Jennifer Saultz, Jenny O'Nions, Faisal Basheer, John Laurie, Shivani Handa, Eytan Stein, Maria Baer, Wendy Stock, Rebecca Olin, William Blum, Gary Schiller, Tara Lin, Emily Curran, Ying Huang, Rina Welkie, Ashley Yocum, Giovanni Marconi, Ellen Madarang, Justin Watts, Yazan Madanat, Richard Dillon, Sanam Loghavi, Joshua Zeidner, Daniel Pollyea, Elsa Bernard
Journal: Blood
Blood (2025) 146 (Supplement 1): 453.
https://doi.org/10.1182/blood-2025-453
Published: 2025
Journal Articles

Outcomes following lower-intensity therapy with venetoclax in patients with NPM1-mutated Acute Myeloid Leukemia are highly dependent upon co-occurring mutations

Free
Curtis Lachowiez, Seongseok Yun, Mael Heiblig, Michael Heuser, Rabia Shahswar, Anand Patel, Rafael Madero-Marroquin, Joseph Cannova, Dimitrios Drekolias, Fatima Tuz Zahra, Amine Belhabri, Urbain Tauveron-Jalenques, Emmanuelle Tavernier, Martin Carre, Gaspar Aspas Requena, Jenny O'Nions, Faisal Basheer, John Laurie, Ellen Madarang, Richard Dillon, Sanam Loghavi, Joshua Zeidner, Dan Pollyea, Justin Watts, Jad Othman
Journal: Blood
Blood (2025) 146 (Supplement 1): 5278.
https://doi.org/10.1182/blood-2025-5278
Published: 2025
Journal Articles

Outcomes and characteristics of patients treated with frontline intensive chemotherapy versus hypomethylating agent/venetoclax-based therapy in DDX41-mutated Acute Myeloid Leukemia (AML)

Free
Fatima Tuz Zahra, Ekrem Turk, Najla Al Ali, Sean Haney, Dimitrios Drekolias, Nicole Vincelette, Jinming Song, Samuel Reynolds, Rory Shallis, Zhuoer Xie, Andrew Kuykendall, Kendra Sweet, Eric Padron, Alison Walker, David Sallman, Rami Komrokji, Jeffrey Lancet, Seongseok Yun, Onyee Chan
Journal: Blood
Blood (2025) 146 (Supplement 1): 291.
https://doi.org/10.1182/blood-2025-291
Published: 2025
Journal Articles

Activity and Safety of Venetoclax (VEN)-Based Treatment in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (R/R MM)

Free
Filip Ionescu, Shrinjaya B Thapa, Parth C Patel, Dimitrios Drekolias, Ariosto Siqueira Silva, Praneeth R Sudalagunta, Phaedra Agius, Brandon Blue, Doris K. Hansen, Omar Castaneda, Hien Liu, Jose L. Ochoa-Bayona, Ciara Louise Freeman, Frederick Locke, Taiga Nishihori, Melissa Alsina, Kenneth H. Shain, Rachid Baz, Ariel Grajales-Cruz
Journal: Blood
Blood (2024) 144 (Supplement 1): 4740.
https://doi.org/10.1182/blood-2024-210069
Published: 2024
Journal Articles

High-Risk Myelodysplastic Syndrome (HR-MDS) Treated with a Hypomethylating Agent (HMA) and Venetoclax - Focus on Antifungal (AF) Prophylaxis and Molecular Subset Outcomes

Free
Jeremy V. DiGennaro, Dimitrios Drekolias, Najla H. Al Ali, Onyee Chan, Seongseok Yun, Alison R. Walker, Zhuoer Xie, Eric Padron, Jeffrey E Lancet, Rami S. Komrokji, David Sallman
Journal: Blood
Blood (2024) 144 (Supplement 1): 1843.
https://doi.org/10.1182/blood-2024-208927
Published: 2024